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a diagnosis of multiple primary tumors.4 In 
our patient, we had identified two different 
truncating germline NTHL1 mutations in trans: 
the above-mentioned c.268C→T,p.Q90* mutation 
and c.709+1G→A, which results in abnormal splic-
ing (Fig. 1B, and Fig. S1 in the Supplementary 
Appendix, available with the full text of this letter 
at NEJM.org). We used several methods to study 
the mutation profile of the tumors (Table S1 and 
Fig. S2 and S3 in the Supplementary Appendix). 
In so doing, we extended the previous report4 
to include benign and malignant extracolonic 
tumors. The mutation spectrum was signifi-
cantly shifted in favor of C:G→T:A transitions 
(Fig. S2 in the Supplementary Appendix), as re-
ported previously.4 Among other driver mutations, 
we identified the frequently reported5 FGFR3 mu-
tation c.742C→T,p.R248C in one seborrheic kera-
tosis (Fig. S3 in the Supplementary Appendix).
A single NTHL1 mutation, p.Q90*, was identi-
fied by investigators in Nijmegen, the Nether-
lands,4 which is only 150 km from Dortmund, 
Germany, where the paternal relatives of our 
patient were born. This finding suggests that 
the p.Q90* allele was inherited paternally. The 
c.709+1G→A mutation has been reported only once 
in 118,482 alleles that were collated by the Exome 
Aggregation Consortium (exac.broadinstitute.org).
This study extends the description of bial-
lelic mutations in NTHL1 beyond the single 
c.268C→T,p.Q90* mutation that was observed 
previously.4 Since the cancer phenotype of bial-
lelic NTHL1 mutations may be very broad, refer-
ring to the “NTHL1 syndrome” could be a useful 
way of describing this condition, rather than fo-
cusing solely on the colorectal phenotype.
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Acquired Resistance to Bedaquiline and Delamanid  
in Therapy for Tuberculosis
To the Editor: Multidrug-resistant tuberculosis 
(MDR-TB) and extensively drug-resistant tubercu-
losis (XDR-TB) are an increasing public health 
threat.1 Bedaquiline and delamanid are two drugs 
that were recently approved by the Food and 
Drug Administration for treatment of MDR-TB 
and XDR-TB.2 Here we describe the stepwise am-
plification of drug resistance in a patient who 
had emigrated from Tibet to Switzerland in De-
cember 2010 and who presented to a Swiss hos-
pital with preextensively drug-resistant tubercu-
losis at that time.
Figure 1 (facing page). Clinical Features, Treatment History, Amplification of Drug Resistance, and Phenotypic Drug-
Susceptibility Testing in the Patient.
Mutations that confer drug resistance are shown. Resistance to bedaquiline, intravenous capreomycin, and delamanid de-
veloped. Percentages on the y axis are based on the number of genome-sequencing reads supporting the corresponding 
drug resistance–conferring mutation (details are provided in Table S4 in the Supplementary Appendix). Large colored 
circles indicate measurements, and dashed lines linking these circles indicate the changes in mutation frequency. The 
loss of the start codon is indicated with an asterisk, and fs indicates frame shift. The mutations listed on the left side of 
the graph were detected in the first and all subsequent isolates obtained from the patient. All these mutations were seen 
in 100% of sequencing reads in each isolate. X indicates the stop codon, and del indicates deletion.  On the x axis, isolate 
numbers are listed under the month when the isolate was obtained. TMP-SMX denotes trimethoprim–sulfamethoxazole.
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correspondence
Genome sequencing revealed that the initial 
Mycobacterium tuberculosis isolate harbored nine 
mutations in genes associated with resistance to 
seven drugs (Fig. 1, and the Supplementary Ap-
pendix, available with the full text of this letter 
at NEJM.org). The isolate also showed a compen-
satory mutation in rpoC,3 indicating a “mature” 
preextensively drug-resistant strain that had evolved 
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Whole-Genome Sequencing
Phenotypic Drug-Susceptibility Testing
Treatment History − +
+ +
RpoB S531L
RpoC D485Y
KatG S315T
RpsL K88R
GyrA D94Y
GyrB V630G
GidB R158L
PncA E107X
EthA F349del
Cycloserine
Intravenous capreomycin
 Aminosalicylic acid
Ethambutol
Bedaquiline
Ethambutol
Intravenous aminosalicylic acid
Intravenous capreomycin
Intravenous cycloserine
Levofloxacin
Meropenem
Clofazimine
Clavulanate
Inhaled amikacin
Delamanid
TMP-SMX
Resistance:
delamanid
Resistance: capreomycin
Resistance: bedaquiline, clofazimine
MmpR V1A*
TlyA A17E
FbiA D49Y
 rrl G2576T
 rrl A2572C
Fgd1 G49fs
Clinical cure Relapse
Clinical cure Relapse
Clinical cure Relapse
Culture:
Smear:
Resistance: isoniazid, rifampicin, pyrazinamide, ethionamide, linezolid, moxifloxacin, streptomycin
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under drug pressure for some time. Given that 
the patient reported no previous treatment for 
tuberculosis, he was probably infected with a 
strain that was already resistant to these drugs.
In September 2011, bedaquiline was added to 
the regimen, which had consisted of four drugs 
(ethambutol, aminosalicylic acid, intravenous 
capreomycin, and cycloserine). The patient was 
considered to be clinically cured in March 2013, 
but he had a relapse in August 2013. Genome 
sequencing of five follow-up isolates revealed a 
mutation in mmpR that was associated with beda-
quiline resistance. This mutation persisted even 
though bedaquiline was discontinued in Febru-
ary 2012; this suggests that it did not cause any 
clinically significant reduction in the virulence 
of the infecting bacteria.4
Additional resistance to second-line injectable 
agents (such as capreomycin) also developed. This 
was reflected in the emergence of mutations in 
tlyA and rrs. The latter mutation remained at low 
frequency and was detected only in drug-contain-
ing bacterial cultures (Table S3 in the Supple-
mentary Appendix). All the molecular findings 
were supported by phenotypic drug-susceptibility 
testing.
Following this amplification in resistance, 
delamanid was added to the regimen in March 
2014. However, two mutations in f biA and fgd1 
increased in frequency by June 2014, which co-
incided with the emergence of phenotypic resis-
tance to delamanid. These genes have previously 
been associated with delamanid resistance. The 
fgd1 mutation decreased in frequency thereafter, 
indicating the presence of multiple delamanid-
resistant clones in the patient. In August and 
September 2014, the patient underwent a lobec-
tomy. After surgery, the sputum specimens ob-
tained from the patient were culture-negative, 
and the patient received treatment on an ambu-
latory basis.
This case highlights the development of resis-
tance in the context of inadequate MDR-TB and 
XDR-TB treatment regimens, despite personalized 
patient care in a well-resourced health care set-
ting. It serves as a warning for the future rollout 
of new antituberculosis drugs and emphasizes 
the need for the use of appropriate companion 
drugs when bedaquiline and delamanid are ad-
ministered. Our results add to previous findings 
showing that the development of drug resistance 
is a dynamic process involving multiple hetero-
geneous populations of bacteria within individ-
ual patients.4,5
Guido V. Bloemberg, Ph.D.
University of Zurich 
Zurich, Switzerland
Sebastien Gagneux, Ph.D.
Swiss Tropical and Public Health Institute 
Basel, Switzerland 
sebastien.gagneux@unibas.ch
Erik C. Böttger, M.D.
University of Zurich 
Zurich, Switzerland
and Others
A complete list of authors is available with the full text of this 
letter at NEJM.org.
Supported by the Swiss Federal Office of Public Health, the Uni-
versity of Zurich, SystemsX.ch, the Novartis Foundation, and grants 
from the Swiss National Science Foundation (PP00P3_150750), 
the National Institutes of Health (AI090928), and the European 
Research Council (309540-EVODRTB). 
Disclosure forms provided by the authors are available with 
the full text of this letter at NEJM.org.
1. Global tuberculosis control — surveillance, planning, financ-
ing. Geneva: World Health Organization, 2014.
2. Zumla A, Memish ZA, Maeurer M, et al. Emerging novel and 
antimicrobial-resistant respiratory tract infections: new drug de-
velopment and therapeutic options. Lancet Infect Dis 2014;14: 
1136-49.
3. Comas I, Borrell S, Roetzer A, et al. Whole-genome sequenc-
ing of rifampicin-resistant Mycobacterium tuberculosis strains iden-
tifies compensatory mutations in RNA polymerase genes. Nat 
Genet 2012;44:106-10.
4. Shcherbakov D, Akbergenov R, Matt T, Sander P, Andersson 
DI, Böttger EC. Directed mutagenesis of Mycobacterium smegmatis 
16S rRNA to reconstruct the in vivo evolution of aminoglycoside 
resistance in Mycobacterium tuberculosis. Mol Microbiol 2010;77: 
830-40.
5. Sun G, Luo T, Yang C, et al. Dynamic population changes in 
Mycobacterium tuberculosis during acquisition and fixation of drug 
resistance in patients. J Infect Dis 2012;206:1724-33.
DOI: 10.1056/NEJMc1505196
Correspondence Copyright © 2015 Massachusetts Medical Society.
instructions for letters to the editor
Letters to the Editor are considered for publication, subject 
to editing and abridgment, provided they do not contain 
material that has been submitted or published elsewhere. 
Please note the following:
• Letters in reference to a Journal article must not exceed 175 
words (excluding references) and must be received within 
3 weeks after publication of the article.
• Letters not related to a Journal article must not exceed 400 
words. 
• A letter can have no more than five references and one figure 
or table. 
• A letter can be signed by no more than three authors.
• Financial associations or other possible conflicts of interest 
must be disclosed. Disclosures will be published with the 
letters. (For authors of Journal articles who are responding 
to letters, we will only publish new relevant relationships 
that have developed since publication of the article.)
The New England Journal of Medicine 
Downloaded from nejm.org at HAUPTBIBLIOTHEK UNIV ZUERICH on December 17, 2015. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
